Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Ingelheim, Germany Boehringer Ingelheim today announces the start of a Phase II clinical trial evaluating its investigational triple GLP-1/GIP/NPY2 receptor agonist, BI 3034701, in patients with obesity and overweight
Those who stopped
GIP (glucose-dependent insulinotropic polypeptide) also enhances insulin secretion and appears to support metabolic efficiency and fat regulation
Summary: GLP-1 receptor agonists do not directly cause sweating, but some patients report changes in perspiration patterns due to indirect factors such as gastrointestinal side effects, hypoglycaemia when combined with other diabetes medications, or autonomic responses to nausea
Thyroid tumors (seen only in animal studies)these medications aren't advised if there's a personal or family history of certain thyroid cancers
US$ 23.22
US$ 23.33
US$ 21.69
US$ 29.82
